Viking Therapeutics Inc

Research Viking Therapeutics Inc (VKTX) on Bullrun: market cap USD 4.59B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerVKTX
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 4.59B
• Financial periodFY2025
• Net income-USD 359.64M

Valuation Snapshot

latest market cap is USD 4.59B.

About Viking Therapeutics Inc

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.

Frequently asked questions

What is Viking Therapeutics Inc's market cap?

Viking Therapeutics Inc's market capitalization is USD 4.59B.

What does Viking Therapeutics Inc do?

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.